The use of infliximab in South-east Asian children with severe Crohn's disease

Lee, W.S. (2004) The use of infliximab in South-east Asian children with severe Crohn's disease. Pediatrics International, 46 (2). pp. 198-201. ISSN 1328-8067

Full text not available from this repository. (Request a copy)
Official URL: http://onlinelibrary.wiley.com/store/10.1046/j.144...

Abstract

Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually need corticosteroid to control symptoms1. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which is important in the pathogenesis of CD2. Infliximab (Remicade, Schering-Plough, Kenilworth, New Jersey, USA), a chimeric anti-TNFα monoclonal antibody, induces remission in patients with moderately to severely active CD and can reduce corticosteroid requirements3. We share our experience in the use of infliximab in three South-east Asian children with severe CD.

Item Type: Article
Uncontrolled Keywords: Crohn's disease;infliximab;perianal disease
Subjects: R Medicine
R Medicine > RJ Pediatrics
Divisions: Faculty of Medicine
Depositing User: Ms Haslinda Lahuddin
Date Deposited: 10 Jul 2014 01:03
Last Modified: 10 Jul 2014 01:03
URI: http://eprints.um.edu.my/id/eprint/10915

Actions (login required)

View Item View Item